Breedon Group plc (LON:BREE)

Market Cap	1.29B
Revenue (ttm)	1.63B
Net Income (ttm)	89.60M
Shares Out	346.52M
EPS (ttm)	0.26
PE Ratio	14.39
Forward PE	11.37
Dividend	0.15 (3.98%)
Ex-Dividend Date	Oct 2, 2025

Volume	719,723
Average Volume	1,700,287
Open	357.60
Previous Close	371.00
Day's Range	357.60 - 373.60
52-Week Range	344.00 - 501.00
Beta	1.13
RSI	47.22
Earnings Date	Jul 23, 2025

About Achilles Therapeutics

Breedon Group plc, together with its subsidiaries, engages in the quarrying, manufacture, and sale of construction materials and building products primarily in the United Kingdom and internationally. It operates through Great Britain, Ireland, United States, and Cement segments. The company offers aggregates, asphalt, block paving, cement, clay bricks and clay products, concrete products, ready-mixed concrete, trowel-ready mortar, roof tiles, and screed. In addition, the company provides mobile concrete and surfacing solutions. Further, it oper...

• Industry: Building Materials
• Sector: Materials
• Founded: 2007
• Employees: 4,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: BREE

Financial Performance

In 2024, Breedon Group's revenue was 1.58 billion, an increase of 5.97% compared to the previous year's 1.49 billion. Earnings were 96.20 million, a decrease of -8.82%.